Therapeutic vaccine for malignant tumors and composition thereof

A technology for therapeutic vaccines and malignant tumors, applied in the field of therapeutic vaccines for malignant tumors and their compositions, and can solve problems such as cell fragmentation

Active Publication Date: 2014-08-06
熊慧
View PDF3 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there are many methods for cell disruption, it is difficul

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic vaccine for malignant tumors and composition thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Embodiment 1: the preparation method of lung cancer vaccine:

[0034] 1. Preparation of human TGF-β2 antisense plasmid:

[0035] The cDNA of human TGF-β2 (NCBI Reference Sequence: NM_003238.3, fragment 1369bp-2613bp) was cloned in the reverse direction into the multiple cloning site MCS of pIRESpuro3 vector, which was confirmed by sequencing. Because the pIRESpuro3 vector contains the promoter and enhancer of CMV, it can replicate in mammals; it contains the internal ribosome entry site (internal ribosome entry site, IRES) of encephalitis myocarditis virus and expresses the gene resistant to puromycin, which can make Antisense mRNA of human TGF-β2 is expressed alone in cells, and only cells expressing antisense mRNA of human TGF-β2 can grow stably under the selection of puromycin. The structure of the pIRESpuro3 plasmid is attached figure 1 shown.

[0036] 2. Preparation of stable cell lines

[0037] Collect four non-small cell lung cancer cell lines in logarithmi...

Embodiment 2

[0052] Embodiment 2: Preparation of Ovarian Cancer Tumor Therapeutic Vaccine

[0053] According to the method described in Example 1, the human TGF-β2 antisense plasmid was transfected into: human ovarian cancer cell A2780, human ovarian cancer cell CoC1, human ovarian cancer cell CoC2, human ovarian cancer cell OVCAR-3, human ovarian cancer cell Ovarian cancer tumor therapeutic vaccines were prepared respectively in cell SK-OV-3 and human ovarian cancer cell line SK-OV-3 / DDP tumor cell line.

[0054] In practical application, multiple tumor cell lines after transfection can be selected according to the different tumor antigenicity of patients, so as to adapt to cancer patients with different differentiations.

Embodiment 3

[0055] Embodiment 3: Preparation of breast cancer tumor therapeutic vaccine

[0056] According to the method described in Example 1, human TGF-β2 antisense plasmids were transfected into: human breast medullary carcinoma cell Bcap-37, human breast ductal carcinoma cell BT474, human breast cancer cell MDA-MB-157, human breast carcinoma cell In ductal carcinoma cells MDA-MB-231, human breast cancer cells MDA-MB-453, human breast adenocarcinoma SK-BR-3, human breast adenocarcinoma MCF-7 tumor cell lines, breast cancer tumor therapeutic vaccine.

[0057] In practical application, multiple tumor cell lines after transfection can be selected according to the different tumor antigenicity of patients, so as to adapt to cancer patients with different differentiations.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a therapeutic vaccine for malignant tumors and a composition thereof. The therapeutic vaccine for malignant tumors is a tumor cell line which contains plasmid of antisense nucleic acid of human transforming growth factor beta (TGF-beta2); the therapeutic vaccine composition for malignant tumors comprises the therapeutic vaccine for malignant tumors and an immunopotentiator, and the immunopotentiator is one selected from the group consisting of a Corynebacterium parvum preparation, a non-cell Corynebacterium parvum preparation, a BCG polysaccharide, a nucleic acid preparation, a Nocardia rubra-cell wall skeleton preparation, a group A Streptococcus preparation, a non-cell group A Streptococcus preparation, a Pseudomonas aeruginosa preparation, a non-cell Pseudomonas aeruginosa preparation, a Brucella preparation, a non-cell Brucella preparation, a non-cell Mycobacterium vaccae preparation and a non-cell Mycobacterium smegmatis preparation, preferably the non-cell Corynebacterium parvum preparation; and the malignant tumors include a lung cancer, a liver cancer, a pancreatic cancer, leukemia, lymphoma, an ovarian cancer, a colon cancer, a stomach cancer and a breast cancer.

Description

technical field [0001] The invention relates to a malignant tumor therapeutic vaccine and its composition. Background technique [0002] At present, malignant tumor is still the number one killer threatening human survival, which seriously interferes with the health of patients and affects the quality of life. The treatment methods mainly include surgery, chemotherapy, radiotherapy and biological therapy. Although most of the tumor cells can be removed by surgery, chemotherapy and conventional treatment and the condition of most patients can be relieved, most of the chemotherapy and radiotherapy have serious side effects on patients. Moreover, these treatment methods cannot achieve the effect of completely eradicating cancer cells, and most patients eventually die of tumor recurrence. Therefore, following surgery, chemotherapy, and radiotherapy, biological therapy has become an important means of comprehensive tumor treatment. At present, tumor biological treatment strateg...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/00A61K45/00A61P35/00C12N15/85C12N5/10
Inventor 熊慧
Owner 熊慧
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap